What is low-risk prostate cancer and what is its natural history?

World Journal of Urology

Volumn 26, Issue 5, 2008, Pages 415-422

  O'Donnell, Helen ^a   Parker, Chris ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Gleason score; Low risk; Prostate cancer; Prostate specific antigen

Indexed keywords

CLASSIFICATION; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; REVIEW; RISK FACTOR;

HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 53549118857     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0277-9     Document Type: Review

References (37)

1. Draisma G, Boer R, Otto SJ et al (2003) Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878
2. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD (2008) The clinical management of patients with a small volume of prostatic cancer on biopsy: What are theArisks of progression?: a systematic review and meta-analysis. Cancer 112:971-981
3. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974
4. Zelefsky MJ, Fuks Z, Hunt M et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876-881
5. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A (2004) A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59:380-385
6. Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170:1792-1797
7. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR (2004) The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149
8. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR (2005) The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol 174:1789-1793 discussion 1793
9. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933-938
10. Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T (2007) Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int 99:554-558
11. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374
12. Haas GP, Delongchamps NB, Jones RF et al (2007) Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99:1484-1489
13. Stephenson AJ, Kattan MW, Eastham JA et al. (2008) Prostate cancer-specific mortality after radical prostatectomy in the prostate-specific antigen era. Abstract no. 9, Proceedings ASCO GU 2008
14. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980
15. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101
16. Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248-1253
17. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277:467-471
18. Chodak GW, Thisted RA, Gerber GS et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248
19. Cuzick J, Fisher G, Kattan MW et al (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95:1186-1194
20. Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984
21. Wilt TJ, Brawer MK (1995) Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): A randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol 13:130-136
22. Donovan J, Hamdy F, Neal D et al (2003) Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 7:1-88
23. Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94:1361-1368
24. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R (1991) Sex or survival: Trade-offs between quality and quantity of life. J Clin Oncol 9:328-334
25. Klotz L (2005) Active surveillance for prostate cancer: For whom? J Clin Oncol 23:8165-8169
26. Roemeling S, Roobol MJ, de Vries SH et al (2007) Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: Characteristics, PSA doubling times, and outcome. Eur Urol 51:1244-1250 Discussion 1251
27. van As NJ, Parker CC (2007) Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 13(5):289-294
28. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J (2007) PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170-174
29. Carter HB, Kettermann A, Warlick C et al (2007) Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178:2359-2364 Discussion 2364-2355
30. de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schroder FH (2004) Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. J Urol 172:2193-2196
31. Hardie C, Parker C, Norman A et al (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95:956-960
32. Steuber T, Vickers AJ, Serio AM et al (2007) Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53:233-240
33. Raaijmakers R, de Vries SH, Blijenberg BG et al (2007) hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 52:1358-1364
34. Fall K, Garmo H, Andren O et al (2007) Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99:526-532
35. Quinn DI, Henshall SM, Sutherland RL (2005) Molecular markers of prostate cancer outcome. Eur J Cancer 41:858-887
36. Borre M, Stausbol-Gron B, Overgaard J (2000) p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 164:716-721
37. Jhavar S, Corbishley CM, Dearnaley D et al (2005) Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer 93:478-482